Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

NCT07012330 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

111

Enrollment

OTHER

Sponsor class

Stopped the number of dropouts and slow recruitment

Conditions

Neuroendocrine (NE) Tumors

Interventions

DRUG: Capecitabine (Xeloda)
DRUG: 177Lu-DOTATATE

Sponsor

Erasmus Medical Center